ArticleFrontiers in neurology2025
Hemiplegic shoulder pain, a combined approach with suprascapular nerve block and intra-articular corticosteroid injections: a case series.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemiplegic shoulder pain (HSP) is a prevalent and disabling condition affecting patients after stroke or traumatic brain injury. There is currently no consensus regarding infiltrative strategies. A combined approach, involving suprascapular nerve block and intra-articular corticosteroid injection, has been proposed for HSP and capsulitis, yet evidence remains limited. Objective: This study presents the results (efficacy and safety) of this combined approach to alleviate pain and improve passive range of motion (PROM). Methods: A retrospective, multicenter observational study (36 patients). Results: At 1 month, the mean pain intensity (visual analogue scale VAS) significantly decreased from 6.5 ± 1.5 at baseline to 1.9 ± 2.1, and PROM showed significant improvement across all three planes (mean PROM gains: 28.4° in abduction, 29.2° in flexion, and 13.4° in external rotation). The benefits were largely maintained at 3 months, and no serious complications were observed (one vasovagal episode). Conclusion: The combined approach is a clinically feasible, safe, and effective method for treating HSP in PRM settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.